Equity Research
William Blair research analyst Margaret Kaczor was quoted by MedTech Dive in its coverage of how biopharma companies are investing in and developing new technology solutions to assist those living with diabetes.
“I think they think it will be big. I think that’s yet to be proven,” Kaczor shared in regards to one company’s investment in its innovations in diabetes technology solutions.
Stay up-to-date with the latest William Blair news and insights
William Blair initiated research coverage of First Advantage Corporation (FA $15.32), a leading global provider of technology-enabled background screening products.
Read moreWilliam Blair initiated research coverage of On Holding AG (ONON $32.87), a fast-growing performance and lifestyle brand based in Switzerland selling athletic footwear, primarily in running, but with a growing presence in newer categories and apparel.
Read moreWilliam Blair initiated research coverage of Cullinan Oncology, Inc. (CGEM $17.37), a company focused on advancing modality-agnostic targeted therapies for cancer, with a broad pipeline encompassing small molecules and multifunctional therapies across a diverse range of oncologic targets.
Read moreInformation contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures
